A carregar...

Cell Therapy for Stroke: Remaining Issues to Address Before Embarking on Clinical Trials

BACKGROUND AND PURPOSE: Stroke remains a significant clinical unmet condition, with only 3% of ischemic patient population benefiting from the thrombolytic drug tissue plasminogen activator largely because of the drug's narrow 3-hour therapeutic window. Extending the stroke therapeutic window w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Stroke
Autor principal: Borlongan, Cesar V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4810678/
https://ncbi.nlm.nih.gov/pubmed/19064801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.108.533091
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!